J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347

Short Report

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)

Marco Bregni, Fabio Ciceri, Jacopo Peccatori

Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy

Abstract

A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.

Keywords: Allogeneic hematopoietic stem cell transplantation, advanced renal cell cancer, graft-versus-tumor.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Bregni M, Ciceri F, Peccatori J. Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347. Available from http://www.jcancer.org/v02p0347.htm